Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Eurand NV

Division of Allergan PLC

Latest From Eurand NV

Forest bets on growth with $2.9bn Aptalis buy

With the $2.9bn acquisition of Aptalis, new Forest Laboratories CEO Brent Saunders is delivering deals in rapid succession to fulfill the company's strategy for growth.

Gastrointestinal Orthopedics

Forest Builds On Saunders’ Strategy With $2.9B Aptalis Buy

The specialty pharma makes its first acquisition of the New Year, tucking in gastrointestinal and cystic fibrosis franchises, which bolster its current therapeutic area offerings.

BioPharmaceutical North America

BioNotebook: TPG's Aptalis files for $500 million IPO, Shire extends offer for ViroPharma

The days before and after Christmas weren’t completely devoid of news. A pair of companies announced plans for initial public offerings, including an IPO for private equity-backed Aptalis. An antibacterial drug developer raised $18 million in a private financing, while a company testing a multiple sclerosis therapy raised $8 million in a secondary offering. A small oncology specialist said it raised more than $3 million in an add-on offering. And Shire extended its tender offer for the $4.2 billion takeover of ViroPharma.

Infectious Diseases Cancer

Deals of the Week: Aptalis For Sale

A report suggests that Aptalis Pharma is on the block, but is the price too high? Also, Quintiles spends some of its IPO war chest on a smaller North Carolina CRO, and Pfizer strikes a diabetes deal with Sanford-Burnham.

BioPharmaceutical United States
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
    • Generic Drugs
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Eurand Group
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Benelux
          • Netherlands
  • Parent & Subsidiaries
  • Allergan PLC
  • Senior Management
  • Gearóid Faherty, Chmn. & CEO
    Robert Becker, PhD, Chief Res. Officer
  • Contact Info
  • Eurand NV
    Phone: (31) 20 673 2744
    Fred. Roeskestraat 123
    Olympic Plaza
    Amsterdam, 1076 EE